A. Skride, J. Feldman, O. Shlobin, S. Sahay, J. Denning, W. Kamau-Kelley, G. Gareth, R. Jones, R. Grewal, S. Hoffman, H. Lazarus, O. Sitbon
{"title":"ELEVATE 2:加入标准护理方案治疗肺动脉高压时,两剂量Rodatristat Ethyl的有效性和安全性的IIB期研究的基线人口统计学特征","authors":"A. Skride, J. Feldman, O. Shlobin, S. Sahay, J. Denning, W. Kamau-Kelley, G. Gareth, R. Jones, R. Grewal, S. Hoffman, H. Lazarus, O. Sitbon","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a3781","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":137806,"journal":{"name":"B59. BREAKING BAD: NEW DRUGS AND FORMULATIONS FOR PULMONARY HYPERTENSION AND RV FAILURE","volume":"40 13","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"ELEVATE 2: Baseline Demographic Characteristics From the Phase IIB Study of the Efficacy and Safety of Two Doses of Rodatristat Ethyl When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension\",\"authors\":\"A. Skride, J. Feldman, O. Shlobin, S. Sahay, J. Denning, W. Kamau-Kelley, G. Gareth, R. Jones, R. Grewal, S. Hoffman, H. Lazarus, O. Sitbon\",\"doi\":\"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a3781\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":137806,\"journal\":{\"name\":\"B59. BREAKING BAD: NEW DRUGS AND FORMULATIONS FOR PULMONARY HYPERTENSION AND RV FAILURE\",\"volume\":\"40 13\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"B59. BREAKING BAD: NEW DRUGS AND FORMULATIONS FOR PULMONARY HYPERTENSION AND RV FAILURE\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a3781\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"B59. BREAKING BAD: NEW DRUGS AND FORMULATIONS FOR PULMONARY HYPERTENSION AND RV FAILURE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a3781","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
ELEVATE 2: Baseline Demographic Characteristics From the Phase IIB Study of the Efficacy and Safety of Two Doses of Rodatristat Ethyl When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension